MRNANASDAQ— Moderna, Inc. Price & Analysis

Moderna, Inc.

HEALTHCARE — BIOTECHNOLOGY

$258.38

+$29.94+13.11%

Market Cap: $99.98B; Large Cap
P/E Ratio: N/A
EPS (TTM): $-8.22
Div. Yield: N/A

Technical Summary

RSI (14)68.15Neutral

SMA (50)$187.78Bullish

SMA (200)$89.50Bullish

MACD12.8111Bullish

Bollinger$189.62 – $252.72Upper

Stochastic73.32Neutral

Theo Outlook

Moderna, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of messenger RNA based therapies and preventive medicines, with operations in the United States, Europe, and other global markets. Its latest reported figures as of the quarter ended June 30, 2026 show trailing twelve month revenue of $2.228 billion, a profit margin of -141.43%, diluted earnings per share of -$8.2154, and a market capitalization of $99.98 billion.

Bull case: quarterly revenue grew 2.11% year over year and the company holds a market capitalization of $99.98 billion. Bear case: the company posted a trailing twelve month profit margin of -141.43%, diluted earnings per share of -$8.2154, and EBITDA of -$2.829 billion.

Main risks include sustained negative margins and earnings. Analysis generated by HeyTheo AI from company and market data. It may be incomplete or inaccurate.

Analysis generated by HeyTheo AI on Nov 4, 2026.

Company Overview

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Fundamental Snapshot

Revenue: $2.23B
EBITDA: $-2.83B
Gross Profit: $-280.00M
Operating Margin: -149.0%
Profit Margin: -141.4%
ROE: -39.2%
Book Value: $17.58
Beta: 0.9
52-Wk High: $258.56
52-Wk Low: $22.28
Volume: 14.63M

Frequently Asked Questions

What does Moderna do?

Moderna, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of messenger RNA based therapies and preventive medicines. It targets infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Where does Moderna's revenue come from?

Moderna reported trailing twelve month revenue of $2.228 billion as of the quarter ended June 30, 2026. Quarterly revenue grew 2.11% year over year in that period. The company generates revenue from its mRNA based therapies and vaccines across multiple therapeutic areas.

How does Moderna compete?

Moderna maintains strategic alliances with entities including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, and others. It advances a pipeline of vaccine candidates for respiratory illnesses, latent viral infections, and cancer vaccines. The company holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A.

What are the main risks for Moderna?

Moderna posted a trailing twelve month profit margin of -141.43% and diluted earnings per share of -$8.2154 as of the quarter ended June 30, 2026. EBITDA stood at -$2.829 billion over the trailing twelve months. The company faces risks from sustained negative margins and earnings in its biotechnology operations.

How is Moderna valued?

Moderna trades at a price to sales ratio of 43.59 times trailing twelve month revenue and a price to book ratio of 14.25 times book value as of the latest data. Trailing price to earnings and forward price to earnings ratios are not reported. Market capitalization is $99.98 billion.